- Time:
With the approval of mRNA vaccines for COVID-19, there is a surge of mRNA therapeutics from malaria, HIV, cancer vaccines to mRNA/gRNA gene-editing treatments for cardiovascular diseases with endless possibilities. Lipid nanoparticles (LNPs) are often the delivery choice to effectively deliver and target the cells of interest. In order to produce safe and effective drugs, manufacturers of these modalities must characterize mRNA and the LNPs. Analytical tools such as LC-MS can accurately provide the necessary information to help address critical quality attributes.
In this GEN webinar, our presenters will describe some of the latest analytical methods to determine LNP composition and impurity profiles using LC-MS and LC-ELSD (evaporative light scattering detector) devices. Additionally, we will also learn how LC-MS can be effectively used to determine mRNA 5′ capping efficiency.
A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelist.
Webinar produced with support from:
Powerful biology accelerating the future of medicine
Principal Scientist
Waters Corporation
Senior Product Marketing Manager
Waters Corporation
